한글목차

세계의 차세대 바이오테라퓨틱스(NGBT) 시장은 2024년 54억 2,000만 달러로 평가되었고, 2030년에는 107억 5,000만 달러에 이를 전망이며, CAGR 12.05%로 성장할 것으로 예측됩니다.

NGBT는 유전자 치료, 세포 치료, RNA 간섭, 단일클론항체 등의 첨단 기술을 활용하여 정확하고 맞춤 치료를 제공하는 바이오 의약품의 혁신적인 도약을 의미합니다. 이들 치료법은 특정 질환 메커니즘을 표적으로 하도록 설계돼 부작용을 최소화하면서 치료 효과를 향상시킵니다. 그 용도 범위는 다방면에 걸쳐, 종래의 치료법에 반응하지 않는 환자에게 새로운 희망을 가져오고 있습니다. 맞춤형 데이터 주도형 헬스케어 솔루션에 대한 수요가 높아지는 가운데 NGBT는 세계 헬스케어 시스템에서 빠르게 보급되고 있습니다. 신체의 자연스러운 메커니즘을 활성화하고 차세대 분자 전략을 활용함으로써 이러한 바이오 치료제는 의료 치료의 패러다임을 재구축하고 있습니다. 지속적인 연구 개발의 돌파구로 NGBT는 복잡하고 이전에는 치료 불가능했던 질환의 치료 가능성을 진행하여 더 나은 임상 결과를 제공하고 환자 케어 표준을 재정의하고 있습니다.

시장 성장 촉진요인

암 이환율 증가

주요 시장 동향

고령화 인구 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 차세대 바이오테라퓨틱스 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 치료 영역별(종양학, 자가면역 질환 및 염증성 질환)
  • 기술별(항체 약물 복합체, 이중 특이성 항체, 항체 단편, 항체 유사 단백질, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 차세대 바이오테라퓨틱스 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 차세대 바이오테라퓨틱스 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 차세대 바이오테라퓨틱스 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 차세대 바이오테라퓨틱스 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 차세대 바이오테라퓨틱스 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 제품 출시
• 합병 및 인수

제13장 세계의 차세대 바이오테라퓨틱스 시장 : SWOT 분석

제14장 경쟁 구도

• Xencor, Inc.
• Regenxbio & Neurimmune AG
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• AstraZeneca Plc.
• F. Hoffmann-La Roche Ltd.
• Kyowa Kirin Co., Ltd
• Seattle Genetics, Inc
• ImmunoGen, Inc
• Ono Pharmaceuticals Co, Ltd

제15장 전략적 제안

제16장 기업 소개 및 면책사항

영문목차

The Global Next Generation Biotherapeutics (NGBT) Market was valued at USD 5.42 billion in 2024 and is projected to reach USD 10.75 billion by 2030, growing at a CAGR of 12.05%. NGBTs signify a transformative leap in biopharmaceutical innovation, utilizing advanced technologies such as gene therapy, cell therapy, RNA interference, and monoclonal antibodies to deliver precise and personalized treatment. These therapies are engineered to target specific disease mechanisms, improving treatment effectiveness while minimizing adverse effects. Their application spans a wide range of conditions, offering new hope for patients unresponsive to conventional therapies. As the demand for tailored, data-driven healthcare solutions grows, NGBTs are rapidly gaining traction across global healthcare systems. By activating the body's natural mechanisms and harnessing next-gen molecular strategies, these biotherapeutics are reshaping medical treatment paradigms. With continuous R&D breakthroughs, NGBTs are advancing the possibilities of treating complex and previously untreatable diseases, offering better clinical outcomes and redefining standards in patient care.

Key Market Drivers

Increasing Incidence of Cancer

The escalating global cancer burden is a major factor propelling the demand for Next Generation Biotherapeutics. Cancer rates are expected to rise by 77% by 2050 compared to 2022, highlighting an urgent need for more precise, effective treatment strategies. Traditional treatments like chemotherapy and radiation are often associated with systemic toxicity and limited efficacy. In contrast, NGBT harnesses advanced genomic profiling to tailor therapies to an individual's unique genetic profile, targeting cancer at its molecular root. These therapies are designed to overcome resistance mechanisms and minimize damage to healthy tissues, enhancing therapeutic precision and patient quality of life. As the need for more adaptable and less invasive therapies intensifies, NGBTs are positioned as a vital component in the evolving landscape of oncology treatment.

Key Market Trends

Increasing Aging Population

The global demographic shift toward an older population is a major trend fueling demand for NGBTs. By 2050, the population aged 65 and above is expected to grow to 16%, further increasing to 24% by 2100. With age comes a heightened prevalence of chronic and degenerative diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. NGBTs provide targeted, innovative therapies tailored to the complex health needs of aging individuals. These biotherapeutics offer a high level of personalization, which is especially critical for elderly patients managing multiple comorbidities. Their potential to reduce hospitalizations and long-term care needs also makes them attractive for healthcare systems aiming to improve outcomes while controlling costs. As aging continues to drive global healthcare demand, NGBTs stand out as a promising solution for personalized, effective disease management in elderly populations.

Key Market Players

• Xencor, Inc.
• Regenxbio & Neurimmune AG
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• AstraZeneca Plc.
• F. Hoffmann-La Roche Ltd.
• Kyowa Kirin Co., Ltd
• Seattle Genetics, Inc
• ImmunoGen, Inc
• Ono Pharmaceuticals Co, Ltd

Report Scope:

In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Biotherapeutics Market, By Therapeutic Area:

• Oncology
• Autoimmune/ Inflammatory Diseases

Next Generation Biotherapeutics Market, By Technology:

• Antibody-Drug Conjugates
• Bispecific Antibodies
• Antibody Fragments
• Antibody-like Proteins
• Others

Next Generation Biotherapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.

Available Customizations:

Global Next Generation Biotherapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Next Generation Biotherapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases)
  • 5.2.2. By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Next Generation Biotherapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Area
  • 6.2.2. By Technology
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Next Generation Biotherapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Area
      • 6.3.1.2.2. By Technology
  • 6.3.2. Canada Next Generation Biotherapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Area
      • 6.3.2.2.2. By Technology
  • 6.3.3. Mexico Next Generation Biotherapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Area
      • 6.3.3.2.2. By Technology

7. Europe Next Generation Biotherapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Area
  • 7.2.2. By Technology
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Next Generation Biotherapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Area
      • 7.3.1.2.2. By Technology
  • 7.3.2. United Kingdom Next Generation Biotherapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Area
      • 7.3.2.2.2. By Technology
  • 7.3.3. Italy Next Generation Biotherapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Area
      • 7.3.3.2.2. By Technology
  • 7.3.4. France Next Generation Biotherapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Area
      • 7.3.4.2.2. By Technology
  • 7.3.5. Spain Next Generation Biotherapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Area
      • 7.3.5.2.2. By Technology

8. Asia-Pacific Next Generation Biotherapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Area
  • 8.2.2. By Technology
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Next Generation Biotherapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Area
      • 8.3.1.2.2. By Technology
  • 8.3.2. India Next Generation Biotherapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Area
      • 8.3.2.2.2. By Technology
  • 8.3.3. Japan Next Generation Biotherapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Area
      • 8.3.3.2.2. By Technology
  • 8.3.4. South Korea Next Generation Biotherapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Area
      • 8.3.4.2.2. By Technology
  • 8.3.5. Australia Next Generation Biotherapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Area
      • 8.3.5.2.2. By Technology

9. South America Next Generation Biotherapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Area
  • 9.2.2. By Technology
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Next Generation Biotherapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Area
      • 9.3.1.2.2. By Technology
  • 9.3.2. Argentina Next Generation Biotherapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Area
      • 9.3.2.2.2. By Technology
  • 9.3.3. Colombia Next Generation Biotherapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Area
      • 9.3.3.2.2. By Technology

10. Middle East and Africa Next Generation Biotherapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Area
  • 10.2.2. By Technology
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Next Generation Biotherapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Area
      • 10.3.1.2.2. By Technology
  • 10.3.2. Saudi Arabia Next Generation Biotherapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Area
      • 10.3.2.2.2. By Technology
  • 10.3.3. UAE Next Generation Biotherapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Area
      • 10.3.3.2.2. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Next Generation Biotherapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Xencor, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Regenxbio & Neurimmune AG
• 14.3. Takeda Pharmaceutical Company Limited
• 14.4. Pfizer, Inc.
• 14.5. AstraZeneca Plc.
• 14.6. F. Hoffmann-La Roche Ltd.
• 14.7. Kyowa Kirin Co., Ltd
• 14.8. Seattle Genetics, Inc
• 14.9. ImmunoGen, Inc
• 14.10.Ono Pharmaceuticals Co, Ltd

15. Strategic Recommendations

16. About Us & Disclaimer